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Congenital chloride diarrhea is due to mutations in the
intestinal Cl/HCO3
 exchange (SLC26A3) which results in
sodium chloride and fluid depletion leading to hypochloremic
and hypokalemic metabolic alkalosis. Although treatment
with sodium and potassium chloride offers protection from
renal involvement in childhood, the long-term renal outcome
remains unclear. Here we describe two cases of congenital
chloride diarrhea-associated end-stage renal disease with
transplantation. Further, we show that there is a high
incidence of mild chronic kidney disease in 35 other patients
with congenital chloride diarrhea. The main feature of the
renal injury was nephrocalcinosis, without hypercalciuria or
nephrolithiasis with small sized kidneys and commensurately
reduced glomerular filtration rates. This suggests that
diarrhea-related sodium chloride and volume depletion, the
first signs of non-optimal salt substitution, promote urine
supersaturation and crystal precipitation. The poor
compliance with salt substitution along with long-lasting
hypochloremic and hypokalemic metabolic alkalosis is likely
to induce progressive calcification and renal failure. Both our
patients developed nephrocalcinosis in the transplanted
kidneys suggesting that this complication is a consequence
of intestinal SLC26A3 deficiency. Interestingly, the transporter
is expressed in the distal nephron but the recurrence of
nephrocalcinosis in the transplanted kidney suggests that
it does not play a significant renal role in this syndrome.
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Congenital chloride diarrhea (CLD) is a rare autosomal
recessive disease.1 The world’s highest incidence—1:30,000 to
1:40,000—occurs in Finland, which accounts for over one-
fifth of the 250 reported cases.2 Over 30 different mutations
in the solute carrier family 26 member 3 (SLC26A3 alias
downregulated in adenoma) gene cause CLD, without
evidence of phenotype–genotype correlation.3–5 SLC26A3
encodes for a Cl/HCO3
 exchanger expressed mainly in
the apical brush border of the intestinal epithelium, in sweat
glands, and in the male reproductive tract.6–8
Even during fetal development, intestinal loss of the
SLC26A3-mediated Cl/HCO3
 exchange causes Cl-rich
diarrhea with secondary loss of Naþ ,9 leading to polyhy-
dramnion and prematurity. Neonatally, watery diarrhea
results in hypovolemia and hypochloremic and hypokalemic
metabolic alkalosis.10 High fecal Cl concentration
(490 mmol/l) is the standard for diagnosis; undiagnosed
CLD is usually lethal.11,12 Oral substitution therapy with
sodium chloride (NaCl) and potassium chloride (KCl) offers
favorable long-term prognosis, but manifestations associated
with extraintestinal expression of SLC26A3 exist: male
subfertility and high sweat Cl.13
Initially, untreated CLD or treatment with KCl substitu-
tion only were reported to cause chronic volume contraction
causing renal impairment.14–16 Thereafter, at least eight
inadequately treated patients worldwide have developed
CLD-associated renal insufficiency.17–24 Renal injury involves
multiple changes, for example, juxtaglomerular hyperplasia,
hyalinized glomeruli, nephrocalcinosis, and vascular
changes.15 Combination therapy with NaCl and KCl at the
recommended Cl (3–4 mmol/kg/day) partly reverses those
renal changes, offering protection from renal involvement
during childhood.11,12
Long-term data on renal survival in treated CLD are
lacking. Although overall outcome in Finnish patients with
CLD is good,13 one patient developed end-stage renal disease
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(ESRD) at the age of 29. Soon after, another patient with
renal transplantation emerged, leading to this first report of
ESRD and renal transplantation as a complication of CLD,
including analysis of renal outcome in 35 Finnish adolescent
and adult patients. Although several other SLC26 transpor-
ters mediate renal Cl/HCO3
 exchange,25–27 evidence of
renal SLC26A3 expression is lacking. To assess whether
SLC26A3 may play a primary role in the kidney, we sought
expression of SLC26A3, in relation to other ion transporters,
in both normal human kidney and in CLD.
RESULTS
Case histories
A boy (case 1) of nonconsanguineous Finnish parents was
born at week 37, after polyhydramnion, birth weight 2870 g
(2 s.d., standard deviation) and height 48 cm (1.8 s.d.).
Neonatally, he produced voluminous stools, and at 4 months,
was hospitalized for vomiting, diarrhea, dehydration, and
hypokalemic and hypochloremic metabolic alkalosis (Kþ
2.8 mmol/l, Cl 57 mmol/l, Naþ 134 mmol/l, pH 7.68),
leading to a CLD diagnosis. Despite KCl substitution (Cl
5 mmol/kg/day), a tendency to hyponatremia (Naþ
125–130 mmol/l) remained. At age 1 year, renal biopsy
revealed narrow tubules with tubular calcifications. At age
5, his salt substitution was modernized to a mixture of NaCl
and KCl (Cl 2.1 mmol/kg/day); thereafter, serum electro-
lytes, growth, and development normalized. At age 6, his
second kidney biopsy showed glomerular hyalinization and
sclerosis, pericapsular and interstitial fibrosis, and abundant
nephrocalcinosis. At age 16, proteinuria (1.2 g/l) and slightly
elevated serum creatinine (125 mmol/l) emerged with normal
blood pressure. Renal biopsy showed progressing injury
(Figure 1a and b). Slowly progressive renal disease occurred,
despite normal electrolyte and acid–base balance with salt
substitution (Cl 2.5 mmol/kg/day). At age 27, he was
hospitalized for hypokalemic and hypochloremic metabolic
alkalosis and renal insufficiency (creatinine 616 mmol/l).
Subtotal parathyroidectomy corrected secondary hyperpar-
athyroidism, but despite increased salt substitution (Cl
2.7 mmol/kg/day), constant alkalosis, hypochloremia, and
hypokalemia continued. At age 28, he started hemodialysis,
and 1 year later, received a cadaver kidney. Thereafter, poorer
compliance with the salt substitution occurred. Three years
after transplantation, a biopsy from the transplant showed
nephrocalcinosis (Figure 1c) comparable with that in his
native kidneys, and reduced glomerular filtration rate (GFR)
(8.3 ml/min per 1.73 m2) emerged. Five years after trans-
plantation, he needed temporary hemodialysis, but for the
Figure 1 | Renal injury in cases with CLD. (a) Native kidney biopsy specimen from case 1, taken at age 19, shows a sclerosed glomerulus
and abundant von Kossa-positive (black) tubular calcifications, which are (b) nonpolarizable, that is, have the same optical properties in all
directions under polarized light. (c) Kidney biopsy specimen from case 1, taken 3 years after transplantation, demonstrates large von Kossa-
positive (black) tubular calcifications and single interstitial calcium deposits. (d) The removed first transplant of case 2 shows moderate
tubular atrophy, luminal dilation, and abundant von Kossa-positive (black) tubular calcifications located in the cortical distal nephrons,
whereas (e) the proximal tubules detected with angiotensin-converting enzyme (ACE) (brown) contain no calcifications. (f) Higher
magnification from the same specimen exemplifies cortical calcification both in the distal tubules and, less abundantly, in the surrounding
interstitium. (g) Polarization microscopy reveals the nonpolarizable nature of these calcificatioms. (h) Kidney biopsy specimen from case 2,
taken 8 weeks after the second transplantation, shows von Kossa-positive (black) tubular calcifications located in the distal tubules. (i) In the
consecutive section, these tubules (arrows) differ from the proximal tubules stained with ACE (brown). Stainings: hematoxylin and eosin
(b, f, g), von Kossa (a, c, d, h), and ACE (e, i). Magnifications:  10 (d, e), and  20 (other micrographs).
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past 3 years, has managed without dialysis despite a serum
creatinine of 600 mmol/l. He has a confirmed homozygous
V317del genotype for CLD, and salt substitution with a dose
of Cl 3 mmol/kg/day.
A 2-year-old girl (case 2) of Polish descent was
hospitalized in Sweden for uremia. She had a history of
diarrhea, urinary tract infections, agenesis of the left kidney,
and renal insufficiency treated in a Polish hospital with
dietary protein restriction. Her height was 74 cm (3.5 s.d.)
and weight 6.5 kg (5 s.d.). Peritoneal dialyses were initiated,
and a special tendency to hypokalemia was treated with KCl
substitution. At age 3, she received a cadaver kidney. The first
signs of nephrocalcinosis emerged 3 weeks after transplanta-
tion, followed by two episodes of rejection, several urinary
tract infections, and subtotal parathyroidectomy for hyper-
parathyroidism. Her tendency to hypokalemia persisted
despite KCl substitution (Cl 0.6 mmol/kg/day). One year
after transplantation, her serum creatinine was 423 mmol/l,
and she had hypokalemic and hypochloremic metabolic
alkalosis (Kþ 3.3 mmol/l, Cl 76 mmol/l, HCO3
 40 mmol/l).
She had a good response to peritoneal dialysis and received
supplemental KCl and NaCl (Cl 4.8 mmol/kg/day). At that
time, low urine Cl (o7 mmol/l) and variable concentra-
tions of fecal Cl (9–103 mmol/l) were measured. At age 5,
this child received her second kidney transplant from her
adoptive father. The first transplant was removed and
assessed (Figure 1d–g). After the second transplantation,
substitution with KCl and NaCl (Cl 2.1 mmol/kg/day) was
required for her tendency toward hypokalemic and hypo-
chloremic metabolic alkalosis, leading to suspicion of CLD 2
months later. Again, high fecal Cl was observed only in
some samples, reflecting the severity of hypochloremia. Salt
substitution with NaCl and KCl (Cl 3.5 mmol/kg/day)
normalized her electrolyte and acid–base balance. Already 8
weeks after transplantation, nephrocalcinosis emerged (Fig-
ure 1h and i). Seven months after transplantation, the child
was hospitalized for acute renal failure, Aspergillus pneumo-
nia, and Staphylococcus epidermidis bacteremia. She recov-
ered, but 5 months later, she developed post-transplantation
non-Hodgkin’s lymphoma, resulting in death at age 6.
Mutation analysis of her SLC26A3 gene confirmed the
CLD-associated homozygous H124L genotype.
Thirty-five Finnish patients with CLD
Of the nine patients (26%) fulfilling the criteria of chronic
kidney disease, eight had either late-diagnosed CLD or
comorbidity probably affecting renal function (Table 1).
Electrolytes, acid–base and fluid balance, calcium-phos-
phate balance, and urine oxalate showed slight abnormalities
in only a few patients, but urine was alkaline (pH47) in 13
(37%). Serum creatinine and arterial blood pressure were
acceptable in all patients (Table 2). None showed marked
hematuria (data not shown).
Relative renal lengths were significantly shorter than
patients’ relative heights, and showed a positive correlation
with GFR values (Figure 2).
To further assess renal function, we divided the patients
into two groups: GFR below (n¼ 20) and above (n¼ 15)
110 ml/min per 1.73 m2. The subgroup with lower GFR levels
did not differ in age, frequency of diarrhea, salt substitution,
or serum electrolytes, but had significantly lower urinary
NaCl, and lower blood pressure (Figure 3a–c). In addition,
erythrocyte sedimentation rates (ESRs), nonspecific measures
of inflammation, were higher among those with lower GFR
Table 1 | Finnish patients with congenital chloride diarrhea and chronic kidney disease
CKD
stage
Sex
(F/M) Age
GFR (ml/
min per
1.73 m2)
Urine
protein
(mg per
24 h)
Height
(s.d.)
Mean
renal
length
(s.d.) Renal ultrasound Probable predisposing factors
1 M 20 112 178 1 0.9 Normal Diagnosis of CLD at 1 month
1 M 21 123 270 +3.4 1 Normal Diagnosis of CLD at 16 days
1 F 25 126 337 0 0.6 Single parenchymal calcification Acute glomerulonephritis at 13
years
1 F 31 92 161 1 0.5 Normal Multiple urinary tract infections
1 F 37 91 35 2 0.6 Increased echogenity, suspected
nephrocalcinosis
Diagnosis of CLD and mild renal
injury at 3 monthsa, hyperuricemia
2 F 18 81 33 0.2 1.4 Diffuse calcification Unspecified colitis, severe
malnutrition
2 F 21 85 64 2.2 2.1 Normal None
2 F 38 78 184 0.4 1.9 Normal Diagnosis of CLD at 2.5 monthsa
and Crohn’s disease at 18 years
2 F 38 77 73 +1.8 1.9 Increased echogenity, suspected
nephrocalcinosis
Diagnosis of CLD at 4 monthsa
5 Mb 36 9.6 324 +1.4 NA Bilateral kidney atrophy with
increased echogenity; normal
ultrasound of the transplant
Diagnosis of CLD at 4 monthsa
(ESRD and renal transplantation at
29 years)
CKD, chronic kidney disease; CLD, congenital chloride diarrhea; ESRD, end-stage renal disease; F, female; GFR, glomerular filtration rate; M, male; NA, not assessed.
Stage 1, kidney damage with normal or increased GFR, stage 2, kidney damage with mildly decreased GFR and stage 5, kidney failure. CKD classification criteria met are shown
in bold.53
aPure KCl therapy in early childhood.
bCase 1 of this study.
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(Figure 3d). Patients with a known inflammatory condition,
Crohn’s disease or unspecified colitis (Table 1), had ESR
levels of 16 and 8 mm/h. Further determinations revealed
correlations between urinary excretion of Ca2þ and of NaCl
(Figure 3e and f).
As urine was alkaline in 37% of our patients (Table 2), we
asked whether Cl depletion in CLD is associated with
compensatory activation of renal Cl/HCO3
 exchange. As
only 2 (6%) of the 35 patients had marked systemic
hypochloremia, we tested whether the subgroup of 15
patients having urine Cl below the reference range
(o83 mmol/day) differed from those with normal excretion
(83–256 mmol/day). Inadequate Cl excretion was associated
with lower urinary Naþ and with higher urinary pH, but no
differences emerged in vein blood HCO3
 or aldosterone
(Figure 4). In addition, no differences existed in salt
substitution, frequency of diarrhea, serum electrolytes, or
plasma renin activity (data not shown). Significantly
increased plasma renin activities appeared only in those
three patients with systemic hypochloremia and metabolic
alkalosis (data not shown).
SLC26A3 expression in the kidney
Variable levels of SLC26A3 mRNA appeared in non-CLD
human kidneys, with a much lower expression than in the
colon (Figure 5a–c). Similarly, the intensity of renal
expression in western blotting was highly variable (Figure
5d). In non-CLD kidneys, SLC26A3 immunoexpression
occurred on the apical membrane of a subset of cells of the
connecting tubule and cortical collecting duct (CCD).
Expression of SLC26A3 appeared in a different cell type
from that of aquaporin-2 (AQP2), a marker for principal
cells.28 The presence of SLC26A3 in the cells with mainly
basolateral and cytoplasmic staining for vacuolar type Hþ -
ATPase (V-ATPase), and apical signal for solute carrier family
26 member 4 (SLC26A4) in the same tubules, suggest that
these cells are either type B or nonA-nonB intercalated cells
(Figure 5e–m).29 All five biopsy samples from healthy
controls were positive for both SLC26A3 and SLC26A4, but
in three of the five nephrectomy samples from kidneys with
focal malignancies, no proteins were detectable by immuno-
histochemistry. The CLD kidney lacked immunoexpression
of SLC26A3 (Figure 5n), although staining for SLC26A4 was
comparable with that of the other samples (Figure 5o).
DISCUSSION
This study shows that despite the protective renal effect of
salt substitution during childhood,16 incidence of renal injury
Table 2 | Laboratory data and blood pressure in 35 patients with congenital chloride diarrhea
Blood tests Daily urine
Na+ (137–149 mmol/l) 143 (138–148) Na+ (30–240 mmol) 126 (26–322)
K+ (3.7–5.3 mmol/l) 4.1 (2.7–5.1) K+ (60–90 mmol) 63 (8–122)
Cl (99–111 mmol/l) 106 (84–112) Cl (85–260 mmol) 86 (0–256)
Mg2+ (0.70–1.00 mmol/l) 0.88 (0.68–1.02) Mg2+ (2.5–7.5 mmol) 3.3 (1.1–9.3)
Ca2+ (2.20–2.65 mmol/l) 2.44 (2.22–2.74) Ca2+ (1.25–5.50 mmol) 2.17 (0.81–5.99)
Pi (0.85–1.40 mmol/l) 1.14 (0.42–2.11) Oxalate (o50 mmol/mol creatinine) 12 (2–54)a
HCO3
 (24–28 mmol/l) 25 (20–33) Pi (19–48 mmol) 34.5 (17–54)
Creatinine (53–115mmol/l) 75 (36–110) pH (5–7) 7 (5–8)
Urea nitrogen (6.4–12 mmol/l) 10 (3.3–16) Protein (o100 mg/day) 64 (22–337)
Renin (2–5 mg/l/h) 2.2 (0.3–31) Arterial blood pressure, systolic (mm Hg) 114 (86–134)
Aldosterone (260–1000 pmol/l) 579 (38–1545) Arterial blood pressure, diastolic (mm Hg) 69 (55–82)
Data are reported as median (range).
aMeasurements performed in 22 patients.
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Figure 2 | Heights, renal lengths and glomerular filtration
rates. (a) Standard deviations (s.d.) for heights (K) were
significantly higher than those of renal lengths (J) in 35 patients
with congenital chloride diarrhea (CLD). Calculated median values
were 0 s.d. for heights and 1.1 s.d. for renal lengths. (b) Relative
renal lengths showed a positive correlation with glomerular
filtration rates (GFR).
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in treated CLD is high. In our Finnish series, one case with
ESRD and nine of 35 with chronic kidney disease total 28%
with renal injury. On the basis of these results, the most
essential factors in preventing CLD-related renal complica-
tions are early diagnostics, optimal salt substitution, and
most importantly, regular follow-up of electrolytes, acid–base
balance, and renal function.
The main feature of CLD-associated renal injury was
nephrocalcinosis, that is, increased kidney Ca2þ content.30
As crystals were nonpolarizable and von Kossa positive
(Figure 1), and urine oxalate levels were normal (Table 2),
these deposits seem to have been calcium phosphate.
Defining the pathophysiology of crystallization in cortical
distal nephrons in CLD requires knowledge of the mechan-
isms of Ca2þ reabsorption. Virtually all of the filtered Ca2þ
is reabsorbed along the nephron, the majority of reabsorp-
tion taking place in the proximal tubule and thick ascending
limb of Henle’s loop. There, Ca2þ reabsorption occurs
through a passive paracellular route in parallel with sodium
reabsorption, with Cl movement acting as an additional
driving force for reabsorption. Only in the distal nephron,
accounting for 10% of Ca2þ reabsorption, movement of
Ca2þ is inversely related to that of Naþ .30–32 Several
inherited tubulopathies, for example, Bartter’s syndrome
involve impaired NaCl transport in the thick ascending limb
of Henle, resulting in failed paracellular reabsorption of
Ca2þ , hypercalciuria, and nephrocalcinosis.30 Despite the
lack of hypercalciuria in CLD, diarrhea-related NaCl deple-
tion9,12—always accompanied by volume depletion and
reduced GFR (Figure 3)—may be important in developing
nephrocalcinosis. To support the severity of hypovolemia,
NaCl depletion, and subsequently increased renal NaCl
absorption, is associated in CLD even with decreased blood
pressure (Figure 3). Only small amounts of NaCl are thus
likely to be delivered to the thick ascending limb and distal
tubule, making impaired Ca2þ reabsorption highly probable.
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Figure 3 | Glomerular filtration rate, urinary electrolytes, blood pressures, and erythrocyte sedimentation rates. Excretion of (a)
urinary Cl and (b) Naþ , and (c) systolic blood pressure (BP) were significantly lower and (d) erythrocyte sedimentation rates (ESRs)
significantly higher among the subgroup of 20/35 patients with congenital chloride diarrhea (CLD) and glomerular filtration rate (GFR)
below 110 ml/min per 1.73 m2. Data are presented as means and 95% confidence intervals. Urinary excretion of Ca2þ showed a positive
correlation with both (e) urinary excretion Cl and (f) Naþ in 35 patients with CLD.
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Figure 4 | Urinary NaCl and pH, vein blood HCO3
, and serum aldosterones. (a) Urinary excretion of Naþ was significantly lower
and (b) urinary pH higher among the subgroup of 15/35 patients with congenital chloride diarrhea (CLD) and urinary Cl excretion below
85 mmol/day. No differences emerged in (c) vein blood HCO3
 or (d) serum aldosterone levels. Data are presented as means and 95%
confidence intervals. Abbreviation ns indicates nonsignifant P value.
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As the primary determinants of saturation are excretion of
calcium salts and water,30 failed paracellular absorption of
Ca2þ , together with coexisting hypovolemia and low urinary
flow, may promote urine supersaturation and crystal
precipitation, without resulting in hypercalciuria in CLD.
This hypothesis may also explain why the earlier KCl therapy
in CLD maintains normal serum electrolytes, but leads to
constant hyperaldosteronism as a sign of Naþ and fluid
depletion, and further to nephrocalcinosis.14–16 In agreement
with our hypothesis, urine volume predicts urinary super-
saturation in children with urolithiasis,33 and increased water
load offers protection from crystallization in adult idiopathic
stone-formers.34 Because crystal-induced epithelial injury in
the distal tubule precedes nephrocalcinosis,35 the higher ESR
levels in our patients with reduced GFR and low NaCl
excretion may indicate not only decline in renal function but
also renal inflammatory response.36 Rather than the disease-
associated risk for intestinal inflammation, elevated ESR
levels often observed in CLD may thus be involved in renal
impairment.13
Of eight patients over age 30, five fullfilled the criteria of
chronic kidney disease. The remaining three had a similar
history of therapy and follow-up, but much earlier diagnoses
of CLD (all before age 4 weeks). Early volume contraction thus
Kidney samples n = 12
Kidney samples n = 12 Kidney
SLC26A3
Colon
Kindney samples
133 kDa
83 kDa
41 kDa
1 2 3 4 5 Colon Liver
M  W
SLC26A3
c
GAPDH
Figure 5 | SLC26A3 in human kidney. (a) Ethidium bromide staining showed variable levels of solute carrier family 26 member 3
(SLC26A3) mRNA, with the expected product size of 348 bp, in 12 samples from human kidney cortex (kidney samples), expression being
significantly higher in the positive control of colon, and absent in both the negative control of skeletal muscle (m), and in water control (w).
The PCR products were purified and sequenced in both directions. (b) GAPDH controls for the 12 samples from the human kidney cortex.
(c) SLC26A3 mRNA was detected also in two commercial cDNA samples from human kidney. (d) Western blotting showed very slight bands
of B75 kDa in four samples from human kidney cortex (1–4) and in one commercial sample (5) from human kidney, the positive control
being colon, and negative control liver. (e) Apical staining for SLC26A3 (brown) was present only in a subset of cells of the connecting
tubule (CNT) (upper positive tubule) and cortical collecting duct (CCD) (lower positive tubule), shown also (f) in higher magnification.
(g) Negative control stained with the SLC26A3 preimmune serum. In the CCD of the medullary rays, (h) expression of SLC26A3 (brown)
appeared apically in a few cells differing from (i) the principal cells positive for aquaporin 2 (AQP2) in the consecutive section (brown).
(j) In the CNT, positive labeling for SLC26A3 (brown) was present in the cell type with mainly basal and cytoplasmic labeling for vacuolar
type Hþ -ATPase (V-ATPase) (red). (k) Similarly, cells in the CCD with the apical signal (arrows) for SLC26A3 (brown) had mainly basal
and cytoplasmic labeling for V-ATPase (red). Both the apical signal for (l) solute carrier family 26 member 4 (SLC26A4) and (m) SLC26A3
emerged in the CCD, one apical cell outline (arrow) even suggesting localization in the same cell in consecutive sections. The kidney sample
of the patient with CLD showed (n) lack of expression of SLC26A3 but (o) positive signal for SLC26A4 (arrows) in the consecutive section.
Magnifications:  20 (e, g–i),  40 (f),  63 (l–o), and  100 (j, k).
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seems to play a critical role in CLD-related renal involvement.
Normal renal function in our 11-year-old patient with CLD
diagnosed late, at age 5, suggests, however, a role for individual
compensatory mechanisms. Even so, as the number of
episodes with even slight NaCl and volume depletion is likely
to increase with age, risk of renal involvement may change
accordingly. Fortunately, rapidly progressive calcification and
renal failure seem to require long-lasting hypochloremic and
hypokalemic metabolic alkalosis, and probably further hyper-
phosphatemia and its associated hyperparathyroidism, as seen
in both our cases. Case 2 exemplified the ultimate condition
with CLD undiagnosed until the second transplantation.
Transplanted kidneys, potentially with ischemic damage, and
considering cyclosporine toxicity, may be especially prone to
renal injury and nephrocalcinosis.35
The unique finding of CLD and a solitary kidney in case 2
occurred, most probably, by chance. In contrast, our
ultrasonic data together with a finding of renal hypoplasia
in late-diagnosed CLD24 suggest that the chronic tendency to
hypovolemia affects renal growth. Kidney sizes of only three
patients fell greater than 2 s.d. below their mean height for
age, however. Small kidneys correlated, as expected,37 with
lower GFR values, meaning that poor renal growth may
predispose to renal involvement in CLD.
Many studies have failed to show SLC26A3 expression in the
kidney, neither in humans nor in mice.3,7,38 Our results
demonstrating low-level expression of SLC26A3 mRNA in the
human kidney (Figure 5) are, however, consistent with a past
finding39 and with low-level labeling of SLC26A3 protein
(Figure 5) in this study. SLC26A3 may thus play only a minor
role in the kidney cortex, probably in the connecting tubule and
CCD, where the final regulation of acid–base and NaCl balance
occurs.40 Although SLC26A4 is the major Cl/HCO3
 exchanger
in both B and non-A/non-B-type intercalated cells,26 metabolic
alkalosis is a feature neither of SLC26A4 deficiency in Pendred
syndrome41 nor in pendrin-knockout mice under basal
conditions.26 Similarly, the loss of SLC26A3 in CLD is not
associated with renal Cl wasting, whereas renal function of
Slc26a3-deficient mice remains unreported.42 These disease-
associated features, at least the partially similar sites of
expression, and the close structural similarity (60%) of
SLC26A3 and SLC26A443 raise a question whether lack of
function of one transporter could be compensated for function
of the other. Corresponding reciprocal upregulation of Slc26a3
occurs in the pancreatic duct of Slc26a6-knockout mice,
allowing normal HCO3
 and fluid secretion.44 In the presence
of the major exchanger Slc26a6, however, pancreatic expression
of Slc26a3 is low if not absent.3,44
Because systemic Cl depletion alone upregulates renal
Slc26a4 in the B intercalated cells,45,46 the low urinary Cl
together with higher pH in our patients may reflect
upregulation of renal Cl/HCO3
 exchange. Normally,
virtually all filtered HCO3
 is reabsorbed, and volume
contraction even enhances reabsorption.31 If distal nephron
Naþ delivery is low, however, inhibition of Hþ pumping
from the A intercalated cells results in alkaline urine.47 In our
study, those with the highest urinary pH were not those with
the lowest urinary Naþ , suggesting renal modulation of
Cl/HCO3
 exchange. Higher urinary pH therefore may
attenuate development of metabolic alkalosis in CLD, but
also promote intratubular crystallization during the inade-
quate NaCl delivery to the distal tubule.30
If upregulation of SLC26A3 occurred in the presence of
chloride or potassium depletion, similarly to that seen for
renal Slc26a4 and Slc26a7,45,46,48 it could in many respects
explain the inconsistent data on renal SLC26A3 expression.
To support this hypothesis, variable levels of renal SLC26A3
mRNA and protein were detectable by reverse transcriptase–
PCR and western blotting. In contrast, the lack of
immunostaining for both SLC26A3 and SLC26A4 in three
of five cancer samples implied nonoptimal specimen quality.
Alternatively, as SLC26A3, alias downregulated in adenoma,3
is absent from malignant intestinal cells, it may also be
downregulated in cancer-affected kidneys.
In conclusion, SLC26A3 may play a minor role in renal
homeostasis. Post-transplant recurrence of nephrocalcinosis
reveals, however, that disrupted SLC26A3-mediated anion
transport plays hardly any role in the pathogenesis of CLD-
related renal injury. Owing to a high risk for chronic kidney
disease, CLD is worth remembering as a rare cause of ESRD.
In the chronic phase, its clinical features may be masked by
those of uremia, making recognition of the underlying
intestinal disorder challenging.
METHODS
Patients with CLD and ESRD
Two patients with CLD-associated ESRD and renal transplantation
were identified: a Finnish man with a homozygous V137del
genotype (case 1) and a Swedish girl with a homozygous H124L
genotype (case 2). Their medical data were reviewed from birth. One
kidney biopsy specimen from case 1, taken before transplantation at
age 19, was available for immunohistochemistry. Biopsy slides from
kidney transplants, stained with hematoxylin and eosin or von Kossa
stain for calcium deposits, were available from both cases. To stain
proximal tubules from consecutive sections, mouse monoclonal
antibody against angiotensin-converting enzyme (1:2500; sc-23908;
Santa Cruz Biotechnology, Santa Cruz, CA) and Novolink TM
detection system (Leica Microsystems, Wetzlar, Germany) were
used. All specimens were examined under polarized light to
differentiate calcium phosphate (nonpolarizable, von Kossa posi-
tive) from calcium oxalate (polarizable, von Kossa negative).
Clinical analysis of 35 Finnish patients
Altogether 35 patients with CLD, 15 males and 20 females, were
enrolled. Subjects’ mean age was 22.1 (range, 10–38) years, with CLD
diagnosis at a mean age of 1 (range, 0–14) month, excluding a boy
with his diagnosis at 4.9 years.13 Diagnoses of CLD included high
fecal Cl (490 mmol/l), in addition to mutation analysis of the
SLC26A3 gene in 29 (83%) patients; 28 had a homozygous V317del
genotype and 1 a heterozygous V317del/344delT genotype. Then, the
mean dose of Cl in substitution therapy with NaCl and KCl was
2.8 mmol/kg/day.
The patients were examined at pediatric units of the university
hospitals in Helsinki, Oulu, or Kuopio. Investigations included
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height measurement, 24-h blood pressure recording, renal ultra-
sound, and assessment of renal lengths as s.d.49,50 Laboratory tests
comprised vein blood–gas analysis, serum Kþ , Naþ , Cl, Ca2þ ,
Mg2þ , Pi, urea nitrogen, creatinine, and aldosterone concentrations,
and plasma renin activity. Standardization of the different
aldosterone analyses (DiaSorin RIA and DPC RIA) was performed
in the laboratory of the Helsinki University Hospital. Urine analyses
(24-h collection) included pH and concentrations of Kþ , Naþ , Cl,
Ca2þ , Mg2þ , Pi, and protein. Urine oxalate concentrations, relative
to urine creatinine, were measured in 22 (63%) patients (Finnish
Institute of Occupational Health, Finland). 51Cr-EDTA clearances
were measured to estimate GFR.
Antibodies
Antiserum was raised in rabbits against the synthetic peptide
FNPSQEKDGKIDFT corresponding to amino acids 724–737 of the
SLC26A3 cDNA (Genbank: L02785). Peptide synthesis and antibody
production were acquired from Research Genetics (Huntsville, AL).7
The following affinity-purified polyclonal antibodies were
used in immunohistochemistry: rabbit anti-human V-ATPase B
(sc-20943; Santa Cruz Biotechnology),51 rabbit anti-rat AQP2
(AQP21-A; Alpha Diagnostics, San Antonio, TX),52 and mouse
anti-human Pendrin (alias SLC26A4; MBL, Woburn, MA).26
Preimmune serum for SLC26A3, and normal rabbit/mouse
immunoglobulin G served as negative controls.
Immunohistochemistry
Archival human kidney samples from the Department of Pathology,
HUSLAB, Helsinki University Hospital, were five histologically
healthy nephrectomy specimens from patients with focal nephro-
blastoma or renal cell carcinoma, and five kidney biopsy samples
from healthy kidney donors.
Formalin-fixed and paraffin-embedded specimens were cut into
B5-mm sections and mounted on glass slides. Antigens were
retrieved by boiling in 10 mM citrate buffer (pH 6.0) for 20 min,
and immunohistochemistry was performed with EnVision kits
(Envisionþ System K4010, and Doublestain system K1395; DakoCy-
tomation, Carpinteria, CA) according to manufacturer’s instructions.
The sections were incubated for 10 min in 3% normal goat serum in
Tris hydrochloride (pH 7.6), and with the primary antibodies SLC26A3
(1:350), AQP21-A (1mg/ml), or SLC26A4 (0.25mg/ml) for 60 min at
room temperature. The slides were stained with diaminobenzidine
for 8 min, and counterstained with Mayer’s hematoxylin (Merck,
Darmstadt, Germany). In double-stained slides, diaminobenzidine was
followed by the blocking agent of the kit supplier, incubation with the
V-ATPase (1:1000) antibody for 30 min, staining with Fast Red for
4 min, and counterstaining with hematoxylin.
Western blotting
Cortical specimens from healthy human kidneys (n¼ 4), not needed
for transplantation, were homogenized in Laemmli sample buffer
with 5% b-mercaptoethanol. Commercial human tissue lysates from
kidney, colon (positive control), and liver (negative control) came
from Zyagen Laboratories, San Diego, CA. After loading 20–30 mg of
each sample onto 9% polyacrylamide gel, electrophoresis followed,
and proteins were transferred onto Hybond-C extra nitrocellulose
membrane (Amersham Pharmacia Biotech, Bucks, UK) using
standard protocols. After blocking with 5% nonfat dry milk in
Tris-buffered HCl Tween-20, pH 7.6, the membranes were incubated
with the SLC26A3 antiserum or preimmune serum (1:350) followed
by incubation with peroxidase-conjugated goat anti-rabbit IgG
(1:4000; Roche Diagnostics, Mannheim, Germany). Chemilumines-
cence was used for visualization of the protein bands (GE
Healthcare, Princeton, NJ).
Reverse Transcriptase–PCR
Frozen cortical samples from normal human kidneys (n¼ 3), not
needed for transplantation, and cortical samples from nine patients
nephrectomized for congenital nephrotic syndrome were homo-
genized and used for total RNA extraction with the RNeasy Mini Kit
(Qiagen, Valencia, CA), after which cDNA was synthetized with the
SuperScript III First Strand Synthesis System (Invitrogen, Carlsbad,
CA) by use of random hexamers. The quality of cDNA was ensured
by PCR for GAPDH (Applied Biosystems, Foster City, CA). Control
cDNA samples were from human cDNA panels (kidney and skeletal
muscle; Clontech, Mountain View, CA), and from Gene Pool cDNA
(colon and kidney; Invitrogen).
Amplification for SLC26A3 was performed with primers 50-
AAACACCGTAGGAGATTGCTTC-30 and 30-ATCAGCATTCCCTT
TAAGTTTCC-50. PCR assays were prepared in 25-ml volumes
containing 4 ml cDNA template, 200 mM of each nucleotide, 0.4 mM of
both primers, 4% dimethyl sulfoxide, 1 Phusion GC Buffer, and
0.02 U/ml Phusion High-Fidelity DNA polymerase (Finnzymes Oy,
Espoo, Finland). Touch-down PCR protocol was: 98 1C for 30 s, 35
cycles of 98 1C for 10 s, 60 1C minus 0.5 1C per cycle for 30 s, and
72 1C for 1 min 30 s, without final extension. PCR products of
348 bp, corresponding to nucleotides 1010–1357 of the published
SLC26A3 cDNA, were subjected to electrophoresis on a 2% agarose
gel. The products were purified with ExoSAP-IT (USB, Cleveland,
OH) and sequenced in both directions (ABI 3730xl DNA Analyzer;
Applied Biosystems).
Statistics and ethics
Mann–Whitney U-test and Spearman’s correlation coefficients (rs)
served in comparison of data. Significance was set at Po0.05. The
study protocol was approved by the institutional review board, and
informed consent obtained.
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